Treatment outcomes of female germ cell tumors: The Egyptian National Cancer Institute experience

PURPOSE Reported treatment outcomes for patients with advanced germ cell tumors (aGCT) are based mainly on series from developed nations. Data from low- and middle-income countries are underrepresented. MATERIAL AND METHODS From 2000 to 2015, a retrospective analysis identified 300 patients with aGCT treated at our institution. Kaplan-Meier methods were used for analysis of progression-free survival (PFS) and overall survival (OS) according to the International Germ Cell Consensus Classification Group (IGCCCG). RESULTS Patients’ median age was 28 years. According to the IGCCCG, 57% had good-, 18.3% intermediate-, and 24.7% poor-risk disease. Median α-fetoprotein levels were 2.9, 243, and 3,998 ng/mL, and those of human chorionic gonadotropin were 0.4, 113, and 301.5 mUI/mL in IGCCCG good-, intermediate-, and poor-risk groups, respectively. At a median 46 months of follow-up, 93 PFS events and 45 deaths had occurred and estimated 5-year PFS and OS were 69% and 85%, respectively, including 83% and 95.3% in good-risk, 70.9% and 83.6% in intermediate-risk, and 35.1% and 62.2% in poor-risk patients, respectively. In multivariable analysis, Eastern Cooperative Oncology Group performance status ≥ 2 was a significant independent prognostic factor with a hazard ratio of 2.58 (95% CI, 1.55 to 4.29; P < .001) and 6.20 (95% CI, 2.97 to 12.92; P < .001) for PFS and OS, respectively. CONCLUSION Brazilian patients with aGCT in this cohort had similar outcomes as patients in the IGCCCG database. In comparison with contemporary series, patients with intermediate- and poor-risk aGCT had slightly inferior PFS and OS, possibly due to a high percentage of patients with poor performance status and less use of high-dose chemotherapy.

Download Full-text

Treatment Outcomes, Growth Height, and Neuroendocrine Functions in Patients With Intracranial Germ Cell Tumors Treated With Chemoradiation Therapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2011.12.084 ◽

2012 ◽

Vol 84 (3) ◽

pp. 632-638 ◽

Cited By ~ 24

Author(s):

Kazumasa Odagiri ◽

Motoko Omura ◽

Masaharu Hata ◽

Noriko Aida ◽

Tetsu Niwa ◽

...

Keyword(s):

Germ Cell ◽

Treatment Outcomes ◽

Germ Cell Tumors ◽

Chemoradiation Therapy ◽

Intracranial Germ Cell Tumors ◽

Neuroendocrine Functions

Download Full-text

Treatment outcomes of germ cell tumors of ovary: Single institutional study

Journal of Oncology Research ◽

10.30564/jor.v3i1.2705 ◽

2021 ◽

Vol 3 (1) ◽

Author(s):

Sumedha Gargy ◽

Rohit Kumar Jha ◽

Ajit Kumar Kushwaha ◽

Mukunda Kumar

Keyword(s):

Adjuvant Chemotherapy ◽

Germ Cell ◽

Treatment Outcomes ◽

Performance Status ◽

Survival Rates ◽

Germ Cell Tumors ◽

Surgical Oncology ◽

Germ Cell Tumours ◽

Primary Surgery ◽

Neo Adjuvant Chemotherapy

5% of all ovarian tumours are accounted to germ cell tumours (GCT’s). Affecting mostly young women, the highest incidence is seen in second and third decade of life. They are highly malignant but chemosensitive and more curable than their epithelial counterparts. Treating these tumors with effective surgery and combination chemotherapy survival rates have dramatically improved in recent decades. We present our experience of ovarian germ cell tumours in theDepartment of Surgical Oncology, Rajendra Institute of Medical Sciences (RIMS), Ranchi with special emphasis on treatment outcomes. A retrospective review of hospital medical records of patients with ovarian germ cell tumours diagnosed and treated at RIMS from June 2019 to August 2020, was performed. Clinical profile and treatment outcome of patients were recorded. A total of 19 patients met criteria. The median age at diagnosis was 20 years (range 11–42 years) and all had good performance status. All except two patients underwent surgery, 70.6% and 29.4% in upfront and interval debulking surgery (IDS) setting respectively. Fertility preserving surgery was done in 75% patients in the primary surgery group and 60% undergoing IDS. 83.3% patients received BEP as adjuvant chemotherapy whereas 80% as neo-adjuvant chemotherapy. Majority (31.5%) patients had dysgerminoma as final histology, followed by mixed histology(26.3%), yolk sac tumour (15.7%), immature teratoma (15.7%) and choriocarcinoma (10.5%) 47.3% patients were in Stage I at the time of diagnosis. 78.9% patients were alive without disease, 10.5% recurred, and 10.5% were lost to follow up.

Download Full-text

Clinical Characteristics and Treatment Outcomes of Patients with Malignant Extracranial Germ Cell Tumors: A 20-Year Single-Center Experience

Güncel Pediatri ◽

10.4274/jcp.2021.0023 ◽

2021 ◽

Vol 19 (2) ◽

pp. 176-184

Author(s):

Funda Tayfun Küpesiz ◽

Gülen Tüysüz ◽

Ayşe Nur Akınel ◽

Ayşegül Tekneci ◽

Ayşe Çiğdem Sivrice ◽

...

Keyword(s):

Germ Cell ◽

Treatment Outcomes ◽

Clinical Characteristics ◽

Germ Cell Tumors ◽

Single Center ◽

Single Center Experience

Download Full-text

High-dose chemotherapy and autologous hematopoietic stem cell transplantation (HCAT) in the treatment of germ cell tumors: Retrospective analysis of The National Cancer Institute-Brasil

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.4791 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4791-4791

Author(s):

D. Herchenhorn ◽

R. Dienstmann

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Germ Cell ◽

Retrospective Analysis ◽

National Cancer Institute ◽

Germ Cell Tumors ◽

High Dose Chemotherapy ◽

High Dose ◽

Hematopoietic Stem

Download Full-text

Retrospective, correlative study of BRAF mutation V600E in testicular cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e15584 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e15584-e15584

Author(s):

Shailesh R. Satpute ◽

Roelof Koster ◽

Katherine L. Nathanson ◽

David J. Vaughn ◽

Costantine Albany ◽

...

Keyword(s):

Germ Cell ◽

Treatment Outcomes ◽

Tumor Tissue ◽

Mature Teratoma ◽

Germ Cell Tumors ◽

Disease Recurrence ◽

Braf V600e Mutation ◽

Braf V600e ◽

Tumor Subtypes ◽

Platinum Refractory

e15584 Background: Presence of BRAF V600E mutation forms the basis of a successful targeted therapy against malignant melanoma. While this mutation is also demonstrated in various other tumor types, its presence in germ cell tumor (GCT) is inconsistent across various studies. In one study, 9 out of 35 (26%) platinum-refractory GCTs were positive for BRAF V600E mutation (Honecker et al, JCO 2009 May 1; 27(13):2129-36). In the current study we tested tumor tissue of patients for BRAF V600E mutation in order to correlate it with known tumor subtypes and treatment outcomes. Methods: We obtained tumor specimen of 59 patients with GCT that were treated at either Indiana University or University of Pennsylvania from 2000 to 2011 and tested them for presence of BRAF V600E mutation by Sanger sequencing with exon 15 specific primers. Out of 59 tumors, 12 (20%) were seminomas and 47 (80%) were non-seminomas. 26 (44%) patients had no recurrence after first line cisplatin-based chemotherapy whereas 33 (56%) patients had either platinum-refractory disease or had a disease recurrence within 2 years of completing chemotherapy. Tumors from 10 patients contained only mature teratoma after chemotherapy. 31 (52%) patients were classified at the time of diagnosis as good risk, 8 (14%) patients as intermediate risk and 20 (34%) patients as poor risk according to international germ cell consensus classification. Results: We found that all 59 tumor tissue were wild-type or lacked BRAF V600E mutation. Appropriate positive and negative controls were used for the assay. Conclusions: BRAF V600E mutation is not a feature of GCT. In our study, we failed to observe any correlation of the mutation with tumor subtypes or with treatment outcomes. Based on this study, BRAF inhibiting drugs may not be beneficial in germ cell tumors.

Download Full-text